Bright Green Corporation announced that it signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA-registered, DEA-licensed and cGMP-certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Green’s position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP) and the DEA, all within the U.S., to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients for U.S. and global markets.
Bright Green sees this as yet another step towards becoming the leading domestic supplier of DEA-controlled, plant-based raw materials to produce cannabinoid, psychedelic and opioid based drugs in the U.S.
The DEA just completed its annual operational procedures for all its Schedule I & II drug cultivation and manufacturing in July.
